Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Corneal Neovascularization - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Pipeline Review, H2 2016, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape. Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively for Corneal Neovascularization. Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Corneal Neovascularization Overview 6 Therapeutics Development 7 Pipeline Products for Corneal Neovascularization - Overview 7 Pipeline Products for Corneal Neovascularization - Comparative Analysis 8 Corneal Neovascularization - Therapeutics under Development by Companies 9 Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes 10 Corneal Neovascularization - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Corneal Neovascularization - Products under Development by Companies 13 Corneal Neovascularization - Products under Investigation by Universities/Institutes 14 Corneal Neovascularization - Companies Involved in Therapeutics Development 15 Amakem NV 15 Gene Signal International SA 16 Corneal Neovascularization - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 aganirsen - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 AMA-0526 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Gene Therapy to Inhibit Vascular Endothelial Growth Factor A for Corneal Neovascularization - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 JDE-006 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Recombinant Protein for Oncology and Ophthalmology - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Corneal Neovascularization - Dormant Projects 33 Corneal Neovascularization - Product Development Milestones 34 Featured News & Press Releases 34 May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation. 34 Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure 35 Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth 36 Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye 36 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Corneal Neovascularization, H2 2016 7 Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Corneal Neovascularization - Pipeline by Amakem NV, H2 2016 15 Corneal Neovascularization - Pipeline by Gene Signal International SA, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Corneal Neovascularization - Dormant Projects, H2 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.